Cargando…
吉非替尼治疗非小细胞肺癌的meta分析
BACKGROUND AND OBJECTIVE: Malignant grade and death rate are very high for non-small cell lung cancer, and geftinib is a new molecule target anticancer drug. The aim of this meta analysis is to evaluate the clinical efficacy and safety of geftinib for non-small cell lung cancer. METHODS: We searched...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999715/ https://www.ncbi.nlm.nih.gov/pubmed/21496435 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.04.09 |
Ejemplares similares
-
吉非替尼联合心包灌注治疗晚期非小细胞肺癌的疗效观察
Publicado: (2018) -
吉非替尼治疗127例晚期复发非小细胞肺癌患者分类及回归树分析
Publicado: (2011) -
EGFR基因rs2293347多态对吉非替尼治疗非小细胞肺癌临床疗效的影响
Publicado: (2011) -
凡德他尼治疗非小细胞肺癌的meta分析
Publicado: (2012) -
替吉奥治疗晚期非小细胞肺癌三线及以上患者的疗效分析
Publicado: (2018)